BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
220.26
+3.55 (+1.64%)
At close: 4:00PM EDT

219.96 -0.30 (-0.14%)
After hours: 7:59PM EDT

Stock chart is not supported by your current browser
Previous Close216.71
Open220.02
Bid219.11 x 1800
Ask219.96 x 900
Day's Range216.12 - 221.87
52 Week Range216.12 - 388.67
Volume5,968,576
Avg. Volume1,702,246
Market Cap43.327B
Beta (3Y Monthly)1.69
PE Ratio (TTM)10.21
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Stocks mixed, Treasury yields fall after Mueller report results
    Yahoo Finance6 hours ago

    Stocks mixed, Treasury yields fall after Mueller report results

    U.S. stocks ended Monday’s session mixed as investors continued to digest global growth concerns and the results of Special Counsel Robert Mueller’s long-anticipated report, which found no proof of coordination between the Trump campaign and Russia during the 2016 presidential elections.

  • TheStreet.com6 hours ago

    Dow Ends Slightly Higher Despite Slowing Global Growth Worries

    The Dow Jones Industrial Average ended higher Monday in cautious trading as global growth concerns continued to weigh on Wall Street. rose 1.6% after its board approved a $5 billion share repurchase program. U.S. Treasury bond yields continued to suggest difficult economic times.

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool7 hours ago

    3 Top Healthcare Stocks to Buy Right Now

    What do a beaten-down biotech, a giant pharmacy chain, and a robotic surgical systems maker have in common? They could all be great stocks to buy.

  • 1 Surprising Reason Alzheimer's Drugs Remain So Elusive
    Motley Fool8 hours ago

    1 Surprising Reason Alzheimer's Drugs Remain So Elusive

    Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary.

  • Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group
    Investor's Business Daily10 hours ago

    Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group

    Major stock indexes rallied off lows Monday. Marijuana stocks were in rally mode ahead of earnings from Cronos Group Tuesday before the open.

  • Barrons.com12 hours ago

    Biogen Stock Likely Won’t See a Boost From Buybacks, Analysts Say

    The biotech announced a $5 billion share-buyback plan, but Jefferies analyst Jared Holz says “stock buybacks [are] seldom value creating” but they could help bolster Biogen stock in the near term.

  • Reuters12 hours ago

    Biogen announces $5 billion buyback days after shelving Alzheimer's trials

    Biogen had lost more than $18 billion of its value last week after the company and partner Eisai Co Ltd ended two late-stage trials of their experimental Alzheimer's disease treatment, aducanumab. Biogen shares, which lost 32.4 percent of their value since the company's announcement on Thursday to scrap the trials, were up 1.5 percent before the opening bell on Monday.

  • TheStreet.com13 hours ago

    Biogen Announces $5 Billion Buyback Just Days After Stock Plunge

    on Monday announced that its board approved a $5 billion share repurchase program - just days after the company said it had ended its trial for what had appeared to be a promising potential Alzheimer's treatment. In a filing with the Securities and Exchange Commission on Monday, Biogen said its approved repurchasing up to $5 billion of the company's common shares outstanding as part of its 2019 share repurchase program. , was deemed unlikely to be successful in producing a treatment for the degenerative disease - an announcement that wiped out nearly $20 billion in market value.

  • Barrons.com13 hours ago

    Avon and Biogen Gain, and 3 Other Stocks Making Moves

    Despite widespread global growth worries, a few stocks were making gains before the market’s open Monday, including Avon Products, Biogen, and Viacom.

  • 5 biotech stocks that could be the next big winners
    MarketWatch14 hours ago

    5 biotech stocks that could be the next big winners

    Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.

  • MarketWatch15 hours ago

    Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge

    Shares of Biogen Inc. bounced 1.7% in premarket trade Monday, after the drugmaker disclosed that it set a new $5.0 billion stock repurchase program, without an expiration date. The new program is in addition to the $1.7 billion remaining under the program set in August 2018. The new buyback announcement comes after the stock plummeted 32.4% to close Friday at the lowest level since June 2016, after the company said it would discontinue its phase 3 trials of its Alzheimer's treatment, citing results of an interim analysis of trial data. Based on Friday's stock closing price of $216.71, the total buyback authorization would represent about 30.92 million shares, or 15.7% of the shares outstanding. Biogen's stock has shed 16.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has gained 2.7% and the S&P 500 has advanced 8.2%.

  • Biogen stock plummets 28% after company halts Alzheimer’s trials
    MarketWatch15 hours ago

    Biogen stock plummets 28% after company halts Alzheimer’s trials

    Shares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an investigational drug designed to treat symptoms of early Alzheimer’s disease.

  • Investing.com18 hours ago

    Stocks - Viacom Jumps in Premarket, Nike, Apple Drop, Boeing Gains

    Investing.com - Stocks in focus in premarket trade Monday:

  • Is It Safe to Buy Biogen Stock Right Now?
    InvestorPlaceyesterday

    Is It Safe to Buy Biogen Stock Right Now?

    On Thursday, shares of Biogen (NASDAQ:BIIB) were hammered, falling more than 29% in just one session. Biogen stock was again under pressure on Friday, falling almost 3% on the day. The move puts the stock down massively on the week and below key support.Source: Biogen via YouTubeBut what's got BIIB stock under pressure in the first place?On Thursday morning, Biogen announced that it and development partner Eisai would terminate two stage 3 clinical trials for their Alzheimer's treatment, aducanumab. As InvestorPlace's Aaron Levitt put it (linked above): "The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere."InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has many investors trapped above at higher prices, with some investors wondering if now's the time to get long. Let's digest the charts here. Trading Biogen Stock Click to EnlargeDespite axing what many were hoping would be a robust treatment, Biogen's fundamentals are still intact. However, the charts are not. Above is a five-year weekly chart highlighting just how much technical damage was dealt out over the past two days. * The 10 Best ETFs to Buy in the Second Quarter It's crazy how much can change in one day. With Biogen stock, we have the stock plunging through the 10-week, 50-week and 200-week moving averages, as well as falling below key support. $250 has been long-time support, buoying BIIB stock for much of the past five years. The exception came in 2016, when Biogen stock broke below this mark for about six months.When that happened, $230 stood tall, but even that mark failed to prop up Biogen this time. What are investors going to do? A retest of the lows near $210 certainly seems to be in the cards now, but the rebound is what has me concerned. Should BIIB stock bounce, bulls need to see what role $250 plays. If this mark acts as resistance, Biogen could be a tough one to own for a while. If it gives way and the stock is able to get back above this mark, then BIIB has a chance to reclaim its prior range.Aggressive bulls could justify a new position in Biogen stock with a stop-loss near the 2016 lows. Conservative bulls may want to wait for a possible retest of those lows or at least a further decline before starting to nibble.In either case, $250 will be an important test at some point. Valuing BIIB StockDespite the technical thrashing, the fundamentals still look attractive. Revenue estimates call for just 2.2% growth this year to $13.75 billion, while earnings expectations call for 9.4% growth to $28.67 per share. That leaves Biogen stock trading at a very low valuation, at just 7.7 times this year's earnings.It would be one thing if Biogen had negative earnings and revenue expectations for this year and next year. But that's not the case, while cash flow generation remains strong. Over the past 12 months, BIIB has generated free cash flow of more than $5.3 billion. That leaves BIIB stock trading at about 8.4 times its trailing free cash flow.Guys, these aren't expensive numbers here, even with the disappointing Alzheimer's news and the lack of robust growth. That said, the discount to the stock price isn't surprising. Just look at a company like Celgene (NASDAQ:CELG), which has forecast for double-digit earnings and revenue growth this year and next year, yet trades at just 8.5 times this year's earnings. And that's with a pending buyout offer from Bristol-Myers Squibb (NYSE:BMY).I would rather be long CELG (and for that matter, I am) than Biogen stock at this point. That said, long-term investors could justify soon nibbling a position in the latter as it nears a potential capitulation low.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, he was long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Is It Safe to Buy Biogen Stock Right Now? appeared first on InvestorPlace.

  • Benzinga2 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...

  • 2 Biotech Takeout Targets Perfect for Biogen
    Motley Fool2 days ago

    2 Biotech Takeout Targets Perfect for Biogen

    A midsize acquisition seems imminent, and these two would fit like a glove.

  • Morningstar3 days ago

    Primecap's Biogen Exposure Could Be History Repeating

     Biogen's BIIB March 21, 2019, share price drop of 29.2% on news that it has discontinued late-stage trials of an Alzheimer's treatment hurt few asset managers more than Pasadena-based Primecap Management Company. As of year-end 2018, Primecap firmwide owned 7.5% of Biogen's shares outstanding. All six Primecap strategies owned Biogen, but its Vanguard funds had the most exposure.

  • Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study
    Investor's Business Daily3 days ago

    Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study

    Biogen and Japanese pharma Eisai announced a new study in Alzheimer's disease treatment Friday following a high-profile failure on Thursday that sent Biogen stock into a tailspin.

  • Current Stock Market Reverses Lower But Apple, Amazon Strong; Boeing 737 Max Probe; Biogen Dives: Weekly Review
    Investor's Business Daily3 days ago

    Current Stock Market Reverses Lower But Apple, Amazon Strong; Boeing 737 Max Probe; Biogen Dives: Weekly Review

    The stock market rallied as Apple, Amazon and other big techs soared. The Boeing 737 Max faces a criminal probe. Biogen gave up on an Alzheimer's drug.

  • Benzinga3 days ago

    Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

    Mizuho Securities analyst Salim Syed downgraded Biogen from Buy to Neutral and slashed the price target from $416 to $235. UBS analyst Carter Gould downgraded Biogen from Buy to Neutral and reduced the price target from $395 to $242. Morgan Stanley analyst Matthew Harrison downgraded shares from Overweight to Underweight and slashed the price target from $401 to $210.

  • Barrons.com3 days ago

    Biogen Stock Is Falling Again Because Even a Massive Plunge Doesn’t Make it a Bargain Buy

    Biogen stock was falling again, as more analysts downgraded the shares a day after the failure of its Alzheimer’s treatment led to a bitter 29% plunge.

  • Biogen Stock Crashes on Termination of Alzheimer's Studies
    Zacks3 days ago

    Biogen Stock Crashes on Termination of Alzheimer's Studies

    Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

  • Biogen Stock Fell Too Far on Unfortunate News
    InvestorPlace3 days ago

    Biogen Stock Fell Too Far on Unfortunate News

    Investing in biotech stocks has its up days and its down days. For investors in Biogen (NASDAQ:BIIB) -- and more importantly millions of Alzheimer's patients around the world -- yesterday was a down day. On Thursday, Biogen stock plunged more than 30% on the cancelation of stage 3 clinical trials for a blockbuster Alzheimer's medication.Source: Shutterstock The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere. The question now is whether to cut bait or fish. Was the drop enough to get investors excited about Biogen stock again?Given its huge revenue drivers, now cheaper price and still large pipeline, the answer is a resounding yes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What Happened at Biogen?Biotech stocks trade based on expectations. Something positive happens and then investors send the stock skyward and wait for the next big event to occur. It's all about what's coming down the runway. Expectations build upon that. This is true for large biotech stocks as well.For Biogen, the expectation build-up had to do with its Alzheimer's drug candidate aducanumab. The drug was in the class of monoclonal antibody medications. Basically, aducanumab was designed to break down the beta-amyloid plaques that can build up in the brain. These amyloids interfere with communication between brain cells and cause Alzheimer's and mild dementia. Back in 2014, BIIB saw some serious success with aducanumab during an early-stage study. It actually seemed to reduce the build-ups. * 7 Retail Stocks That Will Continue to Rebound in 2019 Thanks to this very positive early trial, Biogen decided to skip over smaller phase 2 studies and move the medication into larger and more advanced stage 3 testing. The idea was that Biogen could skip through the process and land a Food and Drug Administration (FDA) approval much faster. And there was a good chance for that considering how well it did early on.For Biogen stock, this would have been a major win on several fronts.For starters, there have not been any new Alzheimer's therapies approved in more than 15 years. meanwhile, the Alzheimer's Association pegs more than 5.8 million Americans currently living with the disease. Biogen was looking at a potential blockbuster with huge revenue implications. And it potentially needs that revenue to fill the coming declines in its multiple sclerosis portfolio.Unfortunately for BIIB and Alzheimer's patients, they'll have to wait a bit longer.Biogen and its partner Eisai reported that they would discontinue two late-stage trials for the drug after doing a futility analysis. An independent data-monitoring committee came to the conclusion that aducanumab was "unlikely to meet the primary endpoints" in either study.With expectations for the company to score a major blockbuster, investors abandoned Biogen stock. BIIB fell 30% -- or $90 per share -- and had its worst day of trading in nearly 2 decades. Biogen Stock May Be Worth SnaggingBiogen stock's loss was tremendous and goes to show just how much investors were valuing the drug as part of BIIB's future prospects. But perhaps, investors have taken Biogen down too much on the news.For starters, Biogen isn't a fly by night clinical-stage biotech stock. It's just the opposite. The firm has a portfolio of some pretty big blockbusters already. Thanks to winners like Spinraza and Tysabri, BIIB's portfolio managed to see a 10% jump in sales last year to more than $13.45 billion. Moreover, that portfolio managed to generate more than $5.3 billion in free cash flows and impressive earnings.And it's using those profits in a smart way. The key is that Biogen has been building a full pipeline to create a multi-franchise neurology portfolio. This includes its recent buyout of retinal degeneration specialist Nightstar Therapeutics (NASDAQ:NITE). So yes, losing Alzheimer's does stink, but the biotech's rich pipeline and cash flows give it plenty of wiggle room to buy or develop a pipeline. According to CFO Jeff Capello, adding up cash flows, cash on hand and its ability to leverage up and "you get a $37 billion number, which gives us a lot of capacity to add to the business."It's a song and dance we've heard plenty of times before. But Biogen has the firepower to make it work. It can buy a pipeline successfully.For that pipeline potential and drugs already producing revenues, Biogen stock is going for dirt cheap. After yesterday's 30% haircut, you can now snag the biotech firm at just 8.7x free cash flows and a trailing P/E of just 10.50. That's bargain-basement pricing for a biotech leader. For example, Amgen (NASDAQ:AMGN) can be had for a P/E of 14, while Gilead Sciences (NASDAQ:GILD) is closer to 16. Nibbling at Biogen StockGiven the steep drop and perhaps overreaction that sent Biogen stock into extreme value territory, investors with a longer-term timeline may want to consider snagging some of the firm's shares. * 7 Beaten-Up Stocks to Buy as They Reverse Course The lost of the Alzheimer's drug does hurt, but BIIB still has plenty in the tank to get it through. And with today's valuations, there's a decent margin of safety associated with shares. The time to start buying could be now.Disclosure: At the time of writing, Aaron Levitt held a long position in the iShares NASDAQ Biotechnology Index (IBB) -which holds GILD, BIIB and AMGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Biogen Stock Fell Too Far on Unfortunate News appeared first on InvestorPlace.

  • Company News For Mar 22, 2019
    Zacks3 days ago

    Company News For Mar 22, 2019

    Companies in the news are: BIIB, CAG, DRI, WSM